Melanotan I 10mg

Research

Introductory comments on the peptide

Melanotan‑1, also designated afamelanotide or [Nle⁴, D‑Phe⁷]‑α‑MSH, is a synthetic analog of the natural hormone α‑MSH, belonging to the class of melanocortin peptides. The 13‑amino‑acid peptide differs from native α‑MSH by the substitution of methionine with norleucine at position 4 and the insertion of D‑phenylalanine at position 7, modifications that confer greater enzymatic stability and approximately 1000‑fold increased biological potency. Approved for clinical use in specific conditions such as erythropoietic protoporphyria (EPP), the compound is also widely employed as a research tool in melanogenesis, photoprotection, and tumor biology.

Mechanism of Action and Inhibition

The primary effect of Melanotan‑1 results from its action as an agonist of melanocortin receptors, with predominant affinity for the MC1R subtype expressed on the surface of melanocytes. Binding to MC1R activates the Gs subunit, which in turn stimulates adenylate cyclase, elevating intracellular cAMP levels and promoting protein kinase A (PKA) activation. This signaling cascade culminates in the phosphorylation and activation of the transcription factor MITF, which regulates the expression of central melanogenic genes, including tyrosinase, TRP‑1, and TRP‑2, resulting in increased eumelanin production. The peptide also interacts with other melanocortin receptor subtypes (MC3R, MC4R, and MC5R), although with lower affinity, which may mediate additional effects on processes such as energy homeostasis and sexual function. Proteolytic degradation of the peptide by serum enzymes constitutes the primary mechanism of inhibition of its action, with an estimated plasma half‑life of approximately 30 minutes.

Metabolic Impacts Scientifically Investigated to Date

Although the primary function of Melanotan‑1 is centered on skin pigmentation, experimental studies indicate additional relevant metabolic impacts:

• Appetite modulation: Through activation of MC3R and MC4R, the peptide may influence hypothalamic pathways controlling food intake, reducing appetite and promoting weight loss in preclinical models.
• Regulation of energy homeostasis: Interaction with MC4R, a key receptor in energy balance control, suggests a possible role for the peptide in modulating caloric expenditure and thermogenesis, although human data are limited.
• Effects on the cardiovascular system: Activation of melanocortins may indirectly influence blood pressure and vascular function, although the precise mechanisms remain under investigation.

Investigations in Oncological Models

Melanotan‑1 has been extensively studied in the context of preventing ultraviolet radiation (UVR)-induced skin carcinogenesis. The increase in dermal eumelanin promoted by the peptide confers partial photoprotection, reducing UVR penetration and the formation of pyrimidine dimers in DNA, in addition to activating antioxidant and enzymatic repair pathways mediated by the MC1R receptor. In clinical trials, the compound demonstrated efficacy in reducing the incidence of actinic keratoses and squamous cell carcinomas in organ transplant recipients, a high‑risk population for these tumors. In parallel, the peptide has been used as an experimental tool to investigate the role of the MC1R pathway in regulating the tumor microenvironment and the antitumor immune response in melanomas. It is important to note, however, that case reports describe the emergence of dysplastic nevi and melanomas in association with unregulated use of α‑MSH analogs, although a direct causal relationship has not been firmly established.

Specific Action of the Melanotan‑1 Peptide

The most distinctive action of Melanotan‑1 is its ability to induce systemic photoprotection independently of UV radiation exposure. Through sustained stimulation of eumelanogenesis, the peptide elevates melanin density in the epidermis, increasing the capacity for absorption and dispersion of radiant energy. This property confers a physical and chemical barrier against UVR‑induced damage, reducing oxidative stress, inflammation, and skin mutagenesis, with potential application in the prophylaxis of photoinduced diseases, including phototoxicity in EPP, cutaneous lupus erythematosus, and sunburn. Unlike topical sunscreens, the photoprotective effect of Melanotan‑1 is systemic and prolonged, persisting for months after administration.

Pharmacokinetic Considerations in Research

Pharmacokinetic parameters of Melanotan‑1 have been evaluated in clinical and preclinical studies:

• Absorption: The subcutaneous (SC) route has proven most effective for peptide administration, with rapid absorption and adequate bioavailability for melanogenic effects. Controlled‑release formulations, such as PLGA implants, maintain therapeutic levels for up to three months.
• Distribution: Following SC administration, the peptide distributes systemically, with tropism for the skin and other tissues expressing melanocortin receptors. Conclusive data on its penetration into the central nervous system are lacking.
• Metabolism: Melanotan‑1 is degraded by serum and tissue peptidases into inactive fragments, with a short plasma half‑life (approximately 30 minutes). Nevertheless, the pharmacodynamic effects persist for weeks to months, indicating that the signaling triggered by the peptide continues beyond its presence in the body.
• Elimination: Metabolites resulting from degradation are excreted primarily via the renal route, with no evidence of toxic tissue accumulation.

Other Important Research Relationships

• Relationship with Melanotan‑II: Although structurally similar, Melanotan‑I and Melanotan‑II differ in selectivity and side‑effect profiles. Melanotan‑II exhibits lower specificity for MC1R, interacting with higher affinity with MC3R and MC4R, which confers more pronounced orexigenic and pro‑erectile properties, but also a less favorable safety profile.
• Synergism with UV radiation: Studies demonstrate that Melanotan‑1 can be safely combined with exposure to UV‑B light or sunlight, with a synergistic tanning response, allowing pigmentation to be achieved with lower radiation doses.
• Potential use in pigmentation disorders: Preliminary investigations suggest that the peptide may be useful in treating conditions such as vitiligo and leukoderma, by stimulating repigmentation of areas affected by melanocyte loss.

Final Considerations

Melanotan‑1 represents a valuable tool in biomedical research, acting as a selective agonist of the MC1R receptor and an inducer of the melanogenesis pathway. Its action profile transcends mere cosmetic effects, encompassing applications in photoprotection, skin cancer chemoprevention, and modulation of cutaneous inflammatory processes. Although the approved formulation (afamelanotide) has demonstrated safety in controlled clinical trials, the dissemination of unregulated analogs imposes significant risks, including unpredictable adverse reactions and potential genotoxicity. Future studies should more precisely elucidate the epigenetic mechanisms underlying the prolonged action of the peptide and explore its therapeutic potential in other dermatological and metabolic conditions.

References

Ugwu, S. O., Blanchard, J., Dorr, R. T., Levine, N., Brooks, C. A., Hadley, M. E., Aickin, M., & Hruby, V. J. (1997). Skin pigmentation and pharmacokinetics of Melanotan‑I in humans. Biopharmaceutics & Drug Disposition, 18(3), 243–252. https://doi.org/10.1002/(SICI)1099-081X(199704)18:3<243::AID-BDD12>3.0.CO;2-6

Khavinson, V. K., & Malinin, V. (2005). Peptide regulation of gene expression and aging. Neuroendocrinology Letters, 26(1), 11–16.

Fabrikant, J., & Touloei, K. (2013). A review and update on melanocyte stimulating hormone therapy: afamelanotide. Journal of Drugs in Dermatology, 12(7), 775–779.

Habbema, L., Halk, A. B., & Neumann, M. (2017). Risks of unregulated use of alpha‑melanocyte‑stimulating hormone analogues: a review. International Journal of Dermatology, 56(10), 975–980. https://doi.org/10.1111/ijd.13585

ChemicalBook. (2023). Melanotan 1: mechanisms of action, clinical applications and safety. https://www.chemicalbook.cn/article/melanotan-1-mechanisms-of-action-clinical-applications-and-safety.htm